Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis

Chang Min Lee, Dong Ho Lee, Byung Kyu Ahn, Jae Jin Hwang, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background/Aims: The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF). GERD may cause chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis. Although some studies have suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear. Methods: We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 2003 and March 2015. Results: Mean duration of follow-up was 2.6 ± 2.8 years. Of the 786 patients with IPF, 107 (13.6%) were given diagnoses of GERD, and 103 (13.1%) died due to IPF-related pneumonia or respiratory failure. The prevalence of GERD and the cumulative incidence of de novo GERD increased depending on the period of follow-up in patients with IPF. Patients administered PPI for more than four months had a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P -value = 0.024 in Kaplan-Meier curve). In a univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95% CI, 1.03-1.10; P = 0.001), higher initial forced vital capacity (HR, 0.98; 95% CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95% CI, 0.95-1.00; P = 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality. Conclusions: In Korean patients with IPF, the prevalence of GERD was lower than in other countries. PPI use for at least 4 months may have a protective effect against IPF-related mortality.

Original languageEnglish
Pages (from-to)444-451
Number of pages8
JournalJournal of Neurogastroenterology and Motility
Volume22
Issue number3
DOIs
Publication statusPublished - 2016 Jan 1
Externally publishedYes

Fingerprint

Idiopathic Pulmonary Fibrosis
Proton Pump Inhibitors
Gastroesophageal Reflux
Survival
Mortality
Pulmonary Fibrosis
Vital Capacity
Lung Injury
Proportional Hazards Models
Respiratory Insufficiency
Pneumonia

Keywords

  • Gastroesophageal reflux
  • Idiopathic pulmonary fibrosis
  • Korea
  • Proton pump inhibitor
  • Risk factors

ASJC Scopus subject areas

  • Clinical Neurology
  • Gastroenterology

Cite this

Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis. / Lee, Chang Min; Lee, Dong Ho; Ahn, Byung Kyu; Hwang, Jae Jin; Yoon, Hyuk; Shin, Cheol Min; Park, Young Soo; Kim, Nayoung.

In: Journal of Neurogastroenterology and Motility, Vol. 22, No. 3, 01.01.2016, p. 444-451.

Research output: Contribution to journalArticle

Lee, Chang Min ; Lee, Dong Ho ; Ahn, Byung Kyu ; Hwang, Jae Jin ; Yoon, Hyuk ; Shin, Cheol Min ; Park, Young Soo ; Kim, Nayoung. / Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis. In: Journal of Neurogastroenterology and Motility. 2016 ; Vol. 22, No. 3. pp. 444-451.
@article{961a85d39a5041bd92ca165aab0fde26,
title = "Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis",
abstract = "Background/Aims: The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF). GERD may cause chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis. Although some studies have suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear. Methods: We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 2003 and March 2015. Results: Mean duration of follow-up was 2.6 ± 2.8 years. Of the 786 patients with IPF, 107 (13.6{\%}) were given diagnoses of GERD, and 103 (13.1{\%}) died due to IPF-related pneumonia or respiratory failure. The prevalence of GERD and the cumulative incidence of de novo GERD increased depending on the period of follow-up in patients with IPF. Patients administered PPI for more than four months had a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P -value = 0.024 in Kaplan-Meier curve). In a univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95{\%} CI, 1.03-1.10; P = 0.001), higher initial forced vital capacity (HR, 0.98; 95{\%} CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95{\%} CI, 0.95-1.00; P = 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality. Conclusions: In Korean patients with IPF, the prevalence of GERD was lower than in other countries. PPI use for at least 4 months may have a protective effect against IPF-related mortality.",
keywords = "Gastroesophageal reflux, Idiopathic pulmonary fibrosis, Korea, Proton pump inhibitor, Risk factors",
author = "Lee, {Chang Min} and Lee, {Dong Ho} and Ahn, {Byung Kyu} and Hwang, {Jae Jin} and Hyuk Yoon and Shin, {Cheol Min} and Park, {Young Soo} and Nayoung Kim",
year = "2016",
month = "1",
day = "1",
doi = "10.5056/jnm15192",
language = "English",
volume = "22",
pages = "444--451",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "3",

}

TY - JOUR

T1 - Protective effect of proton pump inhibitor for survival in patients with gastroesophageal reflux disease and idiopathic pulmonary fibrosis

AU - Lee, Chang Min

AU - Lee, Dong Ho

AU - Ahn, Byung Kyu

AU - Hwang, Jae Jin

AU - Yoon, Hyuk

AU - Shin, Cheol Min

AU - Park, Young Soo

AU - Kim, Nayoung

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background/Aims: The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF). GERD may cause chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis. Although some studies have suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear. Methods: We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 2003 and March 2015. Results: Mean duration of follow-up was 2.6 ± 2.8 years. Of the 786 patients with IPF, 107 (13.6%) were given diagnoses of GERD, and 103 (13.1%) died due to IPF-related pneumonia or respiratory failure. The prevalence of GERD and the cumulative incidence of de novo GERD increased depending on the period of follow-up in patients with IPF. Patients administered PPI for more than four months had a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P -value = 0.024 in Kaplan-Meier curve). In a univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95% CI, 1.03-1.10; P = 0.001), higher initial forced vital capacity (HR, 0.98; 95% CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95% CI, 0.95-1.00; P = 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality. Conclusions: In Korean patients with IPF, the prevalence of GERD was lower than in other countries. PPI use for at least 4 months may have a protective effect against IPF-related mortality.

AB - Background/Aims: The prevalence of gastroesophageal reflux disease (GERD) is high in patients with idiopathic pulmonary fibrosis (IPF). GERD may cause chronic microaspiration that leads to repeated subclinical lung injury, which leads to pulmonary fibrosis. Although some studies have suggested that proton pump inhibitors (PPI) were associated with a good prognosis in IPF, their effects remain unclear. Methods: We retrospectively reviewed 786 consecutive adult patients with IPF at Seoul National University Bundang Hospital between April 2003 and March 2015. Results: Mean duration of follow-up was 2.6 ± 2.8 years. Of the 786 patients with IPF, 107 (13.6%) were given diagnoses of GERD, and 103 (13.1%) died due to IPF-related pneumonia or respiratory failure. The prevalence of GERD and the cumulative incidence of de novo GERD increased depending on the period of follow-up in patients with IPF. Patients administered PPI for more than four months had a lower IPF-related mortality rate than patients on PPI less than 4 months (Log-rank P -value = 0.024 in Kaplan-Meier curve). In a univariate and multivariate Cox regression hazard model, younger age (hazard ratio [HR], 1.06; 95% CI, 1.03-1.10; P = 0.001), higher initial forced vital capacity (HR, 0.98; 95% CI, 0.96-0.99; P = 0.004), and longer duration of PPI use (HR, 0.97; 95% CI, 0.95-1.00; P = 0.022), but not a diagnosis of GERD, were significantly associated with lower IPF-related mortality. Conclusions: In Korean patients with IPF, the prevalence of GERD was lower than in other countries. PPI use for at least 4 months may have a protective effect against IPF-related mortality.

KW - Gastroesophageal reflux

KW - Idiopathic pulmonary fibrosis

KW - Korea

KW - Proton pump inhibitor

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84977569131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977569131&partnerID=8YFLogxK

U2 - 10.5056/jnm15192

DO - 10.5056/jnm15192

M3 - Article

AN - SCOPUS:84977569131

VL - 22

SP - 444

EP - 451

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 3

ER -